Characteristics of adverse drug reactions resulting in modifications of antineoplastic therapy plan in patients with breast cancer at a comprehensive cancer center.

IF 0.9 4区 医学 Q4 ONCOLOGY
Saba Marji, Raghad Tawalbeh, Amal AlJammal, Ola Mashni, Nour Faqeer
{"title":"Characteristics of adverse drug reactions resulting in modifications of antineoplastic therapy plan in patients with breast cancer at a comprehensive cancer center.","authors":"Saba Marji, Raghad Tawalbeh, Amal AlJammal, Ola Mashni, Nour Faqeer","doi":"10.1177/10781552251362378","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionAdherence to standard antineoplastic treatment is associated with improved response in breast cancer patients. However, treatment modifications may be necessary for patients who experience significant adverse drug reactions (ADRs). Limited data exist on the characteristics of ADRs that require such modifications. We aimed to evaluate significant ADRs associated with antineoplastic agents in breast cancer patients.MethodsA retrospective observational study was conducted at King Hussein Cancer Center, included significant ADRs experienced by breast cancer patients between January 2018 and December 2020. We recorded patients' characteristics, medications involved, the type of ADRs, and the required treatment modifications, including dose reduction, treatment delay, or discontinuation. Descriptive analysis was performed to report the results.ResultsDuring the study period, 597 significant ADRs were reported in 351 patients, with a mean age of 53 years (11.8 SD). Additionally, 65.5% of patients presented with locally advanced disease. Docetaxel (44%) was the most common agent associated with ADRs. Hematologic and gastrointestinal ADRs were the most frequently reported, accounting for 38.0% and 18.0% of ADRs, respectively. Of the reported ADRs, 61.0%, 26.0%, 13.0% resulted in treatment dose reduction, delay and discontinuation of subsequent cycle, respectively.ConclusionIn this study evaluating a relatively large number of significant ADRs, docetaxel was the most common antineoplastic agent requiring treatment modifications. The most frequent modification was dose reduction. Future studies should be directed to identify measures that may reduce the incidence and severity of the ADRs.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251362378"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552251362378","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

IntroductionAdherence to standard antineoplastic treatment is associated with improved response in breast cancer patients. However, treatment modifications may be necessary for patients who experience significant adverse drug reactions (ADRs). Limited data exist on the characteristics of ADRs that require such modifications. We aimed to evaluate significant ADRs associated with antineoplastic agents in breast cancer patients.MethodsA retrospective observational study was conducted at King Hussein Cancer Center, included significant ADRs experienced by breast cancer patients between January 2018 and December 2020. We recorded patients' characteristics, medications involved, the type of ADRs, and the required treatment modifications, including dose reduction, treatment delay, or discontinuation. Descriptive analysis was performed to report the results.ResultsDuring the study period, 597 significant ADRs were reported in 351 patients, with a mean age of 53 years (11.8 SD). Additionally, 65.5% of patients presented with locally advanced disease. Docetaxel (44%) was the most common agent associated with ADRs. Hematologic and gastrointestinal ADRs were the most frequently reported, accounting for 38.0% and 18.0% of ADRs, respectively. Of the reported ADRs, 61.0%, 26.0%, 13.0% resulted in treatment dose reduction, delay and discontinuation of subsequent cycle, respectively.ConclusionIn this study evaluating a relatively large number of significant ADRs, docetaxel was the most common antineoplastic agent requiring treatment modifications. The most frequent modification was dose reduction. Future studies should be directed to identify measures that may reduce the incidence and severity of the ADRs.

某综合癌症中心乳腺癌患者药物不良反应导致抗肿瘤治疗方案修改的特点
坚持标准的抗肿瘤治疗可改善乳腺癌患者的反应。然而,对于出现严重药物不良反应(adr)的患者,可能需要修改治疗方案。需要进行此类修改的adr的特征数据有限。我们的目的是评估乳腺癌患者中与抗肿瘤药物相关的显著不良反应。方法在侯赛因国王癌症中心进行了一项回顾性观察性研究,纳入了2018年1月至2020年12月期间乳腺癌患者的显著不良反应。我们记录了患者的特征、涉及的药物、不良反应的类型以及所需的治疗修改,包括剂量减少、治疗延迟或停药。对结果进行描述性分析。结果在研究期间,351例患者报告了597例显著不良反应,平均年龄53岁(11.8 SD)。此外,65.5%的患者表现为局部晚期疾病。多西他赛(44%)是与adr相关的最常见药物。血液学和胃肠道不良反应报告最多,分别占总不良反应的38.0%和18.0%。在报告的不良反应中,61.0%、26.0%和13.0%分别导致治疗剂量减少、延迟和中断后续周期。结论本研究评估了相对较多的显著不良反应,多西他赛是最常见的需要修改治疗方案的抗肿瘤药物。最常见的修改是减少剂量。未来的研究应旨在确定可能减少不良反应发生率和严重程度的措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信